Format

Send to

Choose Destination
Alcohol Alcohol. 2012 Jul-Aug;47(4):439-42. doi: 10.1093/alcalc/ags028. Epub 2012 Mar 19.

Abstinence and 'low-risk' consumption 1 year after the initiation of high-dose baclofen: a retrospective study among 'high-risk' drinkers.

Author information

1
Département de Médecine Générale, Faculté de Médecine Paris Descartes--Site Cochin, Université Paris Descartes, 24, rue du Faubourg Saint-Jacques, Sorbonne Paris Cité, 75014 Paris, France. laurent.rigal@parisdescartes.fr

Abstract

AIMS:

The aim of the study was to assess the proportions of 'high-risk' drinkers' abstinent or with 'low-risk' consumption levels 1 year after the initiation of high-dose baclofen.

METHODS:

This is a retrospective 'open' study; the outcome of this study was to assess the level of alcohol consumption in the 12th month of treatment.

RESULTS:

Of the 181 patients included, a follow-up evaluation was possible in 132 patients. The initial alcohol consumption of the 132 patients analysed averaged 182 ± 92 g/day. After 1 year, 80% of the 132 (i.e. 58% of 181) were either abstinent (n = 78) or drinking at low-risk levels (n = 28) in their 12th month of treatment. The mean baclofen dose at 1 year was 129 ± 71 mg/day.

CONCLUSION:

High-dose baclofen should be tested in randomized placebo-controlled trials among high-risk drinkers.

PMID:
22434664
DOI:
10.1093/alcalc/ags028
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center